Inhibrx Biosciences Inc (INBX) USD0.0001

Sell:$14.05Buy:$14.09$0.04 (0.29%)

NASDAQ:0.87%
Market closed | Prices delayed by at least 15 minutes
Sell:$14.05
Buy:$14.09
Change:$0.04 (0.29%)
Market closed | Prices delayed by at least 15 minutes
Sell:$14.05
Buy:$14.09
Change:$0.04 (0.29%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.

Key people

Mark P. Lappe
Chairman of the Board, President, Chief Executive Officer
Kelly D. Deck
Chief Financial Officer
Brendan P. Eckelman
Chief Scientific Officer
Douglas G. Forsyth
Independent Director
Jon Faiz Kayyem
Independent Director
Kimberly J. Manhard
Independent Director
Kristiina S. Vuori
Independent Director
Click to see more

Key facts

  • EPIC
    INBX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US45720N1037
  • Market cap
    $202.52m
  • Employees
    156
  • Shares in issue
    14.48m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.